Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer

LESSONS LEARNED. These negative phase II results for parsatuzumab highlight the challenges of developing an agent intended to enhance the efficacy of vascular endothelial growth factor inhibition without the benefit of validated pharmacodynamic biomarkers or strong predictive biomarker hypotheses. A...

Descripción completa

Detalles Bibliográficos
Autores principales: García‐Carbonero, Rocío, van Cutsem, Eric, Rivera, Fernando, Jassem, Jacek, Gore, Ira, Tebbutt, Niall, Braiteh, Fadi, Argiles, Guillem, Wainberg, Zev A., Funke, Roel, Anderson, Maria, McCall, Bruce, Stroh, Mark, Wakshull, Eric, Hegde, Priti, Ye, Weilan, Chen, Daniel, Chang, Ilsung, Rhee, Ina, Hurwitz, Herbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388369/
https://www.ncbi.nlm.nih.gov/pubmed/28275117
http://dx.doi.org/10.1634/theoncologist.2016-0133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388369/
https://www.ncbi.nlm.nih.gov/pubmed/28275117
http://dx.doi.org/10.1634/theoncologist.2016-0133

Ejemplares similares